Literature DB >> 69483

Expression of histocompatibility (HLA) antigens on tumor cells and normal cells from patients with melanoma.

M A Pellegrino, S Ferrone, R A Reisfeld, R F Irie, S H Golub.   

Abstract

The expression of HLA antigens and beta2-microglobulin (beta2-mu) on cultured melanoma cells originated from 11 patients has been quantitated and compared with that on fibroblasts and cultured human lymphoid cells originated from the same patients. No qualitative or quantitative difference was detected with the exception of one melanoma line. HLA antigens were also quantitated in sera from melanoma patients: two sera reacted with anti-HLA-B7 antibodies although this specificity was not expressed on lymphocytes from whom the sera were obtained. A technique to quantitate HLA antigens on cells developed in the course of this study is described.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 69483     DOI: 10.1002/1097-0142(197707)40:1<36::aid-cncr2820400108>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

Authors:  L Rivoltini; K C Barracchini; V Viggiano; Y Kawakami; A Smith; A Mixon; N P Restifo; S L Topalian; T B Simonis; S A Rosenberg
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

2.  Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.

Authors:  F M Marincola; P Shamamian; T B Simonis; A Abati; J Hackett; T O'Dea; P Fetsch; J Yannelli; N P Restifo; J J Mulé
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1994-07

3.  Oncofoetal antigen I: a target for immune cytolysis of human cancer.

Authors:  N Sidell; R F Irie; D L Morton
Journal:  Br J Cancer       Date:  1979-12       Impact factor: 7.640

4.  In vitro production of human antibody to a tumour-associated foetal antigen.

Authors:  R F Irie; P C Jones; D L Morton; N Sidell
Journal:  Br J Cancer       Date:  1981-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.